2026-02-24 - LD The Hague - GlaxoSmithKline v. Moderna - UPC_CFI_619/2025, UPC_CFI_150262025, UPC-CFI-0002033/2025
- Aktenzeichen:
- UPC_CFI_619/2025, UPC_CFI_150262025, UPC-CFI-0002033/2025
- Datum:
- Spruchkörper:
- Court of First Instance - The Hague (NL) Local Division
- Art:
- Order
- Parteien:
- GlaxoSmithKline Biologicals SA v. Moderna et al.
Kernaussage: The Hague LD issued case management orders in the GSK v Moderna vaccine patent infringement case (EP856 and EP941, mRNA lipid nanoparticle technology).
2026-02-24 - LD The Hague - GlaxoSmithKline
v.
Moderna - UPC_CFI_619/2025, UPC_CFI_150262025, UPC-CFI-0002033/2025
notable
The Hague LD issued case management orders in the GSK v Moderna vaccine patent infringement case (EP856 and EP941, mRNA lipid nanoparticle technology). The court granted GSK's R.263 amendment to add mNEXSPIKE as an infringing product, noting that the original injunction request for products 'and/or further versions or variants thereof' already covered new products — the amendment was merely for clarity. Separately, the amendment met R.263(2) requirements: EMA approval came after the SoC and prior US FDA approval didn't imply European market availability. The court dismissed Moderna's R.9 application to exclude GSK's further arguments and Cryo-TEM evidence from the Reply — these were permitted responses to positions taken by Moderna in the defence. Front-loaded proceedings don't require anticipating every defence in the SoC. Regarding 51 auxiliary requests (24 for EP856, 27 for EP941), the court expressed skepticism about feasibility within 14-month proceedings but refused to dismiss en bloc, ordering GSK to submit a tabular overview mapping ARs to invalidity attacks.